58. 肥大型心筋症 Hypertrophic cardiomyopathy Clinical trials / Disease details

臨床試験数 : 119 / 薬物数 : 163 - (DrugBank : 45) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 161

diseases per page:

Showing 1 to 10 of 119 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05186818 (ClinicalTrials.gov)	February 1, 2022	23/12/2021	CY 6031 Study Will Evaluate the Effects of Treatment With Aficamten (CK-3773274) Over a 24-week Peri ...	A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy ...	Obstructive Hypertrophic Cardiomyopathy (oHCM)	Drug: CK-3773274 (5 mg, 10 mg, 15 mg and 20 mg);Drug: Placebo to match CK-3773274	Cytokinetics	Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.	Recruiting	18 Years	85 Years	All	270	Phase 3	United States
2	NCT05174416 (ClinicalTrials.gov)	January 4, 2022	13/12/2021	A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstruc ...	A Phase III, Randomized, Double-blinded, Placebo-controlled Clinical Study With A Long-term Extensio ...	Obstructive Hypertrophic Cardiomyopathy	Drug: Mavacamten;Drug: Placebo	LianBio LLC	NULL	Recruiting	18 Years	99 Years	All	81	Phase 3	China
3	EUCTR2020-003571-17-IT (EUCTR)	30/11/2021	02/09/2021	An Open-Label Study of CK3773274 for Patients with Symptomatic Hypertrophic Cardiomyopathy(HCM) and ...	An Open-Label Study of CK3773274 for Patients with Symptomatic Hypertrophic Cardiomyopathy(HCM) and ...	Obstructive Hypertrophic Cardiomyopathy(oHCM) MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Name: n/a Product Code: [CK-3773274] INN or Proposed INN: CK-3773274 Other descriptive name: (R ...	CYTOKINETICS, INC.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	54	Phase 2	United States;Spain;Italy
4	NCT04905173 (ClinicalTrials.gov)	November 2021	23/5/2021	Comparison of Squat-to-Stand Maneuver With Amyl Nitrite, Valsalva, and Exercise Stress Echocardiogra ...	Comparison of Squat-to-Stand Maneuver With Amyl Nitrite, Valsalva, and Exercise Stress Echocardiogra ...	Hypertrophic Cardiomyopathy;Hypertrophic Obstructive Cardiomyopathy;Cardiomyopathy, Hypertrophic	Other: Squat-to-stand maneuver;Drug: Amyl nitrite inhalation;Other: Valsalva	Mayo Clinic	NULL	Not yet recruiting	18 Years	N/A	All	200	N/A	United States
5	NCT05135871 (ClinicalTrials.gov)	October 31, 2021	28/10/2021	Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects	An Open-Label, Parallel-Group, Single-Center Phase 1 Clinical Study to Evaluate the Pharmacokinetics ...	Hypertrophic Cardiomyopathy	Drug: Mavacamten	LianBio LLC	NULL	Recruiting	18 Years	60 Years	All	44	Phase 1	China
6	NCT05073094 (ClinicalTrials.gov)	October 6, 2021	19/5/2021	Esmolol for Myocardial Protection in Hypertrophic Obstructive Cardiomyopathy	Myocardial Protection With Esmolol in Patients With Hypertrophic Obstructive CardiomyopathyUndergoin ...	Hypertrophic Obstructive Cardiomyopathy	Drug: Esmolol;Drug: Placebo	Meshalkin Research Institute of Pathology of Circulation	NULL	Recruiting	18 Years	N/A	All	80	Phase 4	Russian Federation
7	EUCTR2020-003571-17-ES (EUCTR)	11/08/2021	14/07/2021	This study is being performed to collect long-term safety and tolerability data of CK-3773274 on pat ...	An Open-Label Study of CK-3773274 for Patients with Symptomatic Hypertrophic Cardiomyopathy(HCM) and ...	obstructive hypertrophic cardiomyopathy(oHCM) MedDRA version: 20.0;Level: PT;Classification code 100 ...	Product Code: CK-3773274 INN or Proposed INN: CK-3773274 Other descriptive name: (R)-N-(5-(5-ETHYL-1,2 ...	Cytokinetics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	54	Phase 2	United States;Spain;Italy
8	NCT05025644 (ClinicalTrials.gov)	August 2021	11/8/2021	Quantitative Assessment of Hypertrophic Obstructive CardiomyopathyWith Intraoperative Three-dimensio ...	Quantitative Assessment of Hypertrophic Obstructive CardiomyopathyWith Intraoperative Three-dimensio ...	Hypertrophic Obstructive Cardiomyopathy	Drug: Pre and post-CPB Drug: Dobutamine Hydrochloride;Drug: Post-CPB Drug: Dobutamine Hydrochloride	University Health Network, Toronto	NULL	Not yet recruiting	18 Years	N/A	All	60	Phase 4	NULL
9	ChiCTR2100048388	2021-07-01	2021-07-06	The prognostic value of myocardial fibrosis in patients with hypertrophic cardiomyopathy	The prognostic value of myocardial fibrosis in patients with hypertrophic cardiomyopathy: a prospect ...	hypertrophic cardiomyopathy	GoldStandard:Clinical outcome;Index test:18FAl-NOTA-FAPI imaging quantitatively detect myocardial fi ...	Beijing Chaoyang Hospital, Capital Medical University	NULL	Pending	14		Both	Target condition:100;Difficult condition:0		China
10	NCT04684290 (ClinicalTrials.gov)	June 30, 2021	16/11/2020	Surgical Septal Myectomy vs Percutaneous Transluminal Alcohol Septal Ablation in Patients With Hyper ...	Surgical Septal Myectomy Versus Percutaneous Transluminal Alcohol Septal Ablation in Patients With H ...	Hypertrophic Cardiomyopathy	Procedure: Alcohol Septal Ablation;Procedure: Surgical Septal Myectomy	St. Antonius Hospital	Erasmus Medical Center	Recruiting	40 Years	75 Years	All	100	N/A	Netherlands

First Previous1 2 3 4 5…12Next Last